(8R,9S,10R,13S,14S)-4-(benzyloxy)-3-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[α]phenanthren-17(2H)-one | 1338324-48-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8R,9S,10R,13S,14S)-4-(benzyloxy)-3-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[α]phenanthren-17(2H)-one
• 英文别名: (8R,9S,10R,13S,14S)-4-(benzyloxy)-3-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17(2H)-one；(8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-4-phenylmethoxy-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-one
• CAS: 1338324-48-3
• 化学式: C₂₆H₃₂O₃
• 分子量: 392.538
• InChiKey: IAQFXDVTJUDXPD-NRUSOEPOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[α]phenanthrene-3,17(4H)-dione 在 Rh₂[(N-(4-dodecylphenyl)sulfonyl)-(S)-prolinate]4 、 3-[(3-羧基苯基)磺酰基]-1,2-三氮杂二烯-2-鎓-1-I去 作用下， 以 乙腈 、 2,3,4-三氟甲苯 为溶剂， 反应 12.5h， 生成 (8R,9S,10R,13S,14S)-4-(benzyloxy)-3-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[α]phenanthren-17(2H)-one
  参考文献：
  名称：

  Convenient method for the functionalization of the 4- and 6-positions of the androgen skeleton

  摘要：

  本文报道了甾体乙烯基重氮化合物的制备和反应活性，提供了一种便捷、对取代基容忍、化学选择性和立体选择性的方法，从共同前体合成4-和6-取代的雄激素类似物。在双铑催化下，O–H插入发生在卡宾位点，生成4-取代的甾体，而在银催化下，O–H插入发生在乙烯位点，生成6-取代的甾体。

  DOI：

  10.1039/c2cc31973j

文献信息

• SUBSTITUTED ANDROST-4-ENE DIONES
  申请人：Emory University

  公开号：EP2556082B1

  公开（公告）日：2017-02-22
• US8969327B2
  申请人：——

  公开号：US8969327B2

  公开（公告）日：2015-03-03
• [EN] SUBSTITUTED ANDROST-4-ENE DIONES<br/>[FR] ANDROST-4-ÈNE DIONES SUBSTITUÉES
  申请人：UNIV EMORY

  公开号：WO2011127232A2

  公开（公告）日：2011-10-13

  The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, inluding benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.